Literature DB >> 21657964

High-dose methotrexate in patients with primary central nervous system lymphoma: does drug exposure really matter?

Markus Joerger1, A D R Huitema, G Illerhaus, A J M Ferreri.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21657964     DOI： 10.3109/10428194.2011.580027

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  2 in total

1.  Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation.

Authors:  Elisabeth Schorb; Benjamin Kasenda; Johannes Atta; Stephan Kaun; Anke Morgner; Georg Hess; Thomas Elter; Nikolas von Bubnoff; Martin Dreyling; Mark Ringhoffer; Stefan W Krause; Günter Derigs; Beate Klimm; D Niemann; Kristina Fritsch; Jürgen Finke; Gerald Illerhaus
Journal:  Haematologica       Date:  2013-01-08       Impact factor: 9.941

2.  Advantages of dose-dense methotrexate protocol for primary central nervous system lymphoma: comparison of two different protocols at a single institution.

Authors:  Hiroshi Aoki; Ryosuke Ogura; Yoshihiro Tsukamoto; Masayasu Okada; Manabu Natsumeda; Mizuho Isogawa; Seiichi Yoshida; Yukihiko Fujii
Journal:  Neurol Med Chir (Tokyo)       Date:  2013-10-25       Impact factor: 1.742
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.